Crispr Therapeutics AG vs Gigacloud Technology Inc — how do they compare? Crispr Therapeutics AG trades at $53.87 (market cap $5.23B), while Gigacloud Technology Inc trades at $51.08 (market cap $1.84B). The key difference: Crispr Therapeutics AG is far larger — about 2.8× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | GCT | |
|---|---|---|
Market Cap | $5.23B | $1.84B |
Sector | Health | Technology |
52-Week High | $76.78 | $53.25 |
52-Week Low | $44.34 | $25.44 |
Enterprise Value | $3.65B | $1.97B |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
GCT trades at $51.25, down 0.78% on the day, with strong technical momentum showing bullish moving averages and key resistance at $53. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.16 beating estimates by 29%, maintaining consistent earnings beats and 10.65% net margins. Revenue growth accelerated to 28% in Q2 2026, reaching $1.5B annually, while cash flow generation remains healthy at $120M net cash flow for 2025.
GCT presents a compelling growth story with attractive valuation at 12.25 P/E ratio and strong analyst support (67% buy ratings). Key risks include competitive pressures in furniture logistics and potential margin compression from expansion costs. The stock's technical overbought condition (RSI above 84) suggests near-term consolidation may precede further upside driven by execution on European expansion and New Classic integration.
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →